Cargando…

Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

PURPOSE: Olaratumab is a recombinant human IgG1 monoclonal antibody against PGDFRα. Olaratumab plus doxorubicin improved survivalversus doxorubicin in an open-label, randomised phase 2 soft tissue sarcoma (STS) trial. We characterised the olaratumab exposure–response relationship for progression-fre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Robin L., Mo, Gary, Baldwin, John R., Peterson, Patrick M., Ilaria, Robert L., Conti, Ilaria, Cronier, Damien M., Tap, William D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373189/ https://www.ncbi.nlm.nih.gov/pubmed/30406840 http://dx.doi.org/10.1007/s00280-018-3723-4

Ejemplares similares

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer
por: Mo, Gary, et al.
Publicado: (2017)

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
por: Villalobos, Victor M., et al.
Publicado: (2019)

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020)

Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
por: Moroncini, Gianluca, et al.
Publicado: (2018)

Olaratumab’s failure in soft tissue sarcoma
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
por: Zuluaga-Sanchez, Santiago, et al.
Publicado: (2018)

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma
por: Yonemori, Kan, et al.
Publicado: (2018)

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
por: Striefler, Jana Käthe, et al.
Publicado: (2020)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
por: Attia, Steven, et al.
Publicado: (2023)

Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
por: Pender, Alexandra, et al.
Publicado: (2017)

Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma
por: Moore, Donald C., et al.
Publicado: (2018)

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
por: Schöffski, Patrick, et al.
Publicado: (2023)

Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy
por: Davis, Elizabeth J, et al.
Publicado: (2017)

Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019)

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
por: McGuire, William P., et al.
Publicado: (2018)

Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts
por: Cornillie, Jasmien, et al.
Publicado: (2019)

The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model
por: Higuchi, Takashi, et al.
Publicado: (2019)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Phase I study of olaratumab in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2019)

Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas
por: Liffers, Sven-T, et al.
Publicado: (2013)

High cumulative doxorubicin dose for advanced soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas
por: Vitfell-Rasmussen, Joanna, et al.
Publicado: (2016)

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter
por: Dang, Jing-Yi, et al.
Publicado: (2022)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Neoadjuvant and adjuvant doxorubicin chemotherapy in a case of feline soft tissue sarcoma
por: Torrigiani, Filippo, et al.
Publicado: (2019)

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors
por: Mascarenhas, Leo, et al.
Publicado: (2021)

Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin
por: Kirilin, Evgeny M., et al.
Publicado: (2022)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin
por: Borlle, Lucia, et al.
Publicado: (2019)

Phase III Soft Tissue Sarcoma Trials: Success or Failure?
por: Lee, Alexander T. J., et al.
Publicado: (2017)

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
por: Merry, Eve, et al.
Publicado: (2021)

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
por: Nielsen, O. S., et al.
Publicado: (1998)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
por: Gong, Jun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pumnlh2i2nec0rbo8felh7jovb